<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CeFAZolin Dosage Information</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            padding: 20px;
            background-color: #f9f9f9;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background-color: #fff;
            border-radius: 10px;
            box-shadow: 0px 4px 8px rgba(0, 0, 0, 0.1);
        }

        h1 {
            color: #fcf2f2;
            font-size: 28px;
            font-weight: bold;
            padding: 10px;
            border: 2px solid #afaaaa;
            border-radius: 10px;
            background-color: #2c8ed0;
            text-align: center; /* Center the text */
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 16px;
            text-align: center;
        }

        th, td {
            padding: 12px;
            border-bottom: 1px solid #ddd;
        }

        th {
            background-color: #f2f2f2;
        }

        .highlight {
            background-color: #c3e6cb;
        }

        .dose-range {
            color: red;
            font-weight: bold;
        }

        .section-title {
            margin-top: 20px;
            font-size: 18px;
            font-weight: bold;
        }

        .section-header {
        background-color: #f2f2f2; /* สีเทาอ่อน */
        font-weight: bold;
        padding: 10px;
        text-align: left; /* ชิดซ้าย */
        border-radius: 5px; /* เพิ่มขอบมน */
        margin-bottom: 10px; /* เพิ่มช่องว่างด้านล่าง */
        }

        .highlight-dose {
        color: #ff5733; /* สีแดง */
        font-weight: bold; /* ข้อความตัวหนา */
        background-color: #fbe9e7; /* สีพื้นหลังแดงอ่อน */
        padding: 5px 10px;
        border-radius: 5px;
    }

        .button-group {
            display: flex;
            justify-content: center;
            gap: 10px;
            margin-top: 20px;
        }

        .back-button, .back-button-secondary {
            padding: 10px 20px;
            font-size: 16px;
            cursor: pointer;
            text-align: center;
            text-decoration: none;
            outline: none;
            color: #fff;
            border: none;
            border-radius: 10px;
            box-shadow: 0 5px #999;
        }

        .back-button {
            background-color: #f44336;
        }

        .back-button:hover {
            background-color: #d32f2f;
        }

        .back-button-secondary {
            background-color: #008CBA;
        }

        .back-button-secondary:hover {
            background-color: #007B9A;
        }

        footer {
            text-align: center;
            color: #00000035;
            font-size: 14px;
            padding: 10px;
            width: 100%;
        }

         hr {
            border: none;
            border-top: 2px solid #ccc; /* ความหนาและสีของเส้น */
            margin: 20px 0; /* ระยะห่างบน-ล่างของเส้น */
            width: 100%; /* เส้นขยายเต็มหน้าจอ */
        }

        .content {
            margin-top: 20px; /* ระยะห่างจากเส้น */
            line-height: 1.6;
        }

        /* Mobile-Specific Adjustments */
        @media (max-width: 600px) {
            body {
                padding: 10px;
            }

            h1 {
                font-size: 20px; /* Reduce font size for mobile */
                padding: 5px; /* Reduce padding */
            }

            hr {
                width: 90%; /* ลดความกว้างของเส้นสำหรับหน้าจอเล็ก */
            }

            .content {
                font-size: 14px; /* ลดขนาดตัวอักษรสำหรับหน้าจอเล็ก */
            }

            .highlight-dose {
                font-size: 20px; /* Adjust font size */
            }

            .section-title {
                font-size: 14px;
            }

            .table-wrapper {
                overflow-x: auto; /* Allow horizontal scrolling */
                margin-bottom: 15px;
            }

            table {
                font-size: 14px; /* Reduce font size */
            }

            th, td {
                padding: 8px; /* Reduce padding for smaller screens */
            }

        }
    </style>
</head>
<body>
        <h1>CeFAZolin Dosage Information</h1>

        <!-- Display the calculated PMA and Postnatal Age -->
        <p><strong>PMA:</strong> {{ pma_weeks }} weeks and {{ pma_days }} days</p>
        <p><strong>Calc.:</strong> {{ calc }} weeks</p>
        <p><strong>Postnatal Age:</strong> {{ postnatal_days }} days</p>
        <p><strong>Birth Weight (BW):</strong> {{ "%.2f" | format(bw) }} kg</p>
        
        <div class="section-title">Calculated Dosage</div>
        <p>Recommended Dose: <span class="highlight-dose">{{ min_dose }} - {{ max_dose }} mg/day</span></p>
        <p>Interval: <span class="highlight-dose">{{ interval }}</span></p>


        
        
        <div class="section-title">Dose</div>
        <p>25 mg/kg/dose IV or IM.</p>

        <div class="section-title">Antibiotic Dosing Chart:</div>
            <p> Renal function and drug elimination are most strongly correlated with Postmenstrual Age (PMA;
            equivalent to Gestational Age plus Postnatal Age). PMA is the primary determinant of dosing
            interval, with Postnatal Age as the secondary qualifier.</p>

    <table>
        <thead>
          <th colspan="3">Dosing Interval Chart</th>
            <tr>
                <th>PMA (weeks)</th>
                <th>Post Natal (days)</th>
                <th>Interval (hours)</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td rowspan="2">&lt;29</td>
                <td>0 to 28</td>
                <td>12</td>
            </tr>
            <tr>
                <td>&gt;28</td>
                <td>8</td>
            </tr>
            <tr>
                <td rowspan="2">30 to 36</td>
                <td>0 to 14</td>
                <td>12</td>
            </tr>
            <tr>
                <td>&gt;14</td>
                <td>8</td>
            </tr>
            <tr>
                <td rowspan="2">37 to 44</td>
                <td>0 to 7</td>
                <td>12</td>
            </tr>
            <tr>
                <td>&gt;7</td>
                <td>8</td>
            </tr>
            <tr>
                <td>&gt;45</td>
                <td>ALL</td>
                <td>6</td>
            </tr>
        </tbody>
    </table>

    
    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Administration</div>
        <p>May be given by IV direct (bolus) injection, IV infusion, or IM injection.<br>
        For IV bolus injection, inject slowly over 3 to 5 minutes at a concentration of 100 mg/mL.<br>
        <strong>For IV infusion,</strong> dilute reconstituted solution to a concentration of <strong>5 to 20 mg/mL and infuse
        over 10 to 60 minutes.</strong><br>
        For IM injection, use a concentration of 225 mg/mL. Maximum 330 mg/mL</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Uses</div>
        <p>Use in neonates is generally limited to perioperative infection prophylaxis and treatment of urinary
        tract and soft tissue infections caused by susceptible organisms, e.g. penicillin-resistant Staph.
        aureus, Klebsiella, and Proteus.</p>

        <p><strong>Infective endocarditis:</strong> The following recommendations are based on a consensus of experts [3] .
The full pediatric guidelines can be found here: https://doi.org/10.1161/CIR.0000000000000298</p>

    <table>
        <thead>
          <th colspan="3">Organism Directed Therapy</th>
            <tr>
                <th>Organism</th>
                <th>First-Choice</th>
                <th>Alternative Choice</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Streptococci</td>
                <td colspan="2"></td>

            </tr>
            <tr>
                <td>Highly susceptible to penicillin G (MBC 0.1 mcg/mL or less); includes most viridans streptococci, groups A, B, C, G nonenterococcal, group D streptococci (S bovis, S equinus)</td>    
                <td>Penicillin G or CefTRIAXone</td>
                <td>Vancomycin or First-generation cephalosporin or CefTRIAXone</td>
            </tr>
            <tr>
                <td>Relatively resistant to penicillin(MBC 0.2 mcg/mL or more); less-susceptible viridans streptococci or enterococci</td>
                <td>Penicillin G or Ampicillin + Gentamicin (for first 2 weeks, or entire course for enterococci)</td>
                <td>Vancomycin + Gentamicin for enterococci or Ampicillin + CefTRIAXone (for AMG-resistant enterococci or AMG-intolerant patient) or CefTRIAXone + Gentamicin (not for enterococcal endocarditis)</td>
            </tr>
            <tr>
                <td>Resistant to penicillin</td>
                <td>Consult an infectious disease specialist.</td>
                <td>---</td>
            </tr>
            <tr>
                <td>Staphylococci (S aureus or coagulase-negative staphylococci) †</td>
                <td colspan="2"></td>
            </tr>
            <tr>
                <td>Penicillin G susceptible (1mcg/mL or less) (rare)</td>
                <td>Penicillin G</td>
                <td>Oxacillin or Nafcillin or First-generation cephalosporin or Vancomycin</td>
            </tr>
            <tr>
                <td>Penicillin G resistant (0.1 mcg/mL)</td>
                <td>Oxacillin or Nafcillin with or without Gentamicin</td>
                <td>Vancomycin (for those highly allergic to beta-lactam antibiotics) or First-generation cephalosporin</td>
            </tr>
            <tr>
                <td>Oxacillin (MRSA) resistant (4 mcg/mL)</td>
                <td>Vancomycin</td>
                <td>Daptomycin for right-sided endocarditis, maybe for left-sided</td>
            </tr>
            <tr>
                <td>Vancomycin resistant or intolerant</td>
                <td>Daptomycin</td>
                <td>Unknown</td>
            </tr>
            <tr>
                <td></td>
                <td colspan="2">†When prosthetic material present add riFAMpin + gentamicin(for first 2 weeks) for all staphylococci</td>
            </tr>
            <tr>
                <td>Gram-negative enteric bacilli</td>
                <td>CefTAZidime or Cefepime or Cefotaxime or CefTRIAXone Plus gentamicin (or tobramycin or amikacin, depending on susceptibility)</td>
                <td>Broad-spectrum penicillin Plus gentamicin (or tobramycin or amikacin)</td>
            </tr>
            <tr>
                <td>HACEK group</td>
                <td>CefTRIAXone or Cefotaxime or Ampicillin-sulbactam</td>
                <td>Ampicillin (when susceptible) Plus aminoglycoside</td>
            </tr>
            <tr>
                <td colspan="3"><strong>KEY:</strong> AMG = aminoglycosides; HACEK = Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; MBC = minimum bactericidal concentration, MRSA = methicillin-resistant Staphylococcus aureus (includes resistance to oxacillin, nafcillin, and cephalosporins).</td>
            </tr>
        </tbody>
    </table>



        <div class="section-title">Intravenous Route</div>
        <div class="section-title">Continuous Infusion:</div>
        <p>Slowly inject one-half the total daily dose over 3 to 5 minutes at a concentration of 75 mg/mL of
        colistin base. Add the remaining half of the total daily dose to a compatible solution. Administer by
        slow IV infusion, starting 1 to 2 hours after the initial dose, over the next 22 to 23 hours. The
        choice of IV solution and the volume used are dictated by the requirements of fluid and electrolyte
        management.</p>

        <div class="section-title">Intermittent Administration:</div>
        <p>Infuse one-half of the total daily dose slowly over 3 to 5 minutes at a concentration of 75 mg/mL
        colistin base every 12 hours. Doses were added to 5 mL of normal saline and infused over 30
        minutes in an observational study of 18 neonates.</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Uses </div>
        <p>Optimal dosing for colistin is unknown. However, a review of adult data suggests higher colistin
        concentrations, which may not be achieved with the manufacturer recommended dosing, and a regimen of
        colistin combined with other antibiotics may be necessary. The safety of higher doses is unknown.</p>

        <p><strong>Gram-negative infections, multi-drug resistant:</strong></p>
        <p><strong>Intermittent IV </strong> colistin in combination with at least one other antibiotic, used for the treatment
        of multi-drug resistant infections, mostly Acinetobacter baumannii and Klebsiella pneumoniae, resulted
        in a 76% favorable clinical outcome in a retrospective study (n=21 treatment courses in 18
        neonates). Microbiological clearance was documented in 17 of the 21 courses. During therapy with
        colisin, 5 patients with severe sepsis and multi-organ dysfunction died. The dose of colistimethate
        sodium ranged from 50,000 to 75,000 IU/kg/day in 3 divided doses [1.7 to 2.5 mg/kg/day of colistin
        base]. Renal impairment developed in 2 neonates, both subsequently died of multi-organ
        dysfunction.</p>

        <p><strong>Aerosolized colistin </strong> either as monotherapy or in combination with other IV
        antibiotics demonstrated potential for treating full-term and pre-term neonates
        with Acinetobacter baumannii (13 of the 16 neonates had multidrug-resistant isolates) ventilator-
        associated pneumonia in 2 retrospective studies. Neither clinical nor laboratory adverse events
        were reported. The dosage of colistin base was 4 mg/kg/dose aerosolized with an ultrasonic
        nebulizer for 15 minutes every 12 hours for a median of 9 days (4 to 14 days) in neonates on a
        ventilator while receiving concurrent IV antibiotics. All of the 16 neonates who received nebulized
        colistin cleared the A baumannii infection. Another regimen was colistimethate sodium 1 million
        international units (33.4 mg colistin base) monotherapy twice daily for an average of 9.1 days (4 to
        22 days).</p>

    <!-- เส้นแบ่ง -->
    <hr>

<title>Organism Directed Therapy</title>
    <style>
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 14px;
            text-align: left;
        }
        th, td {
            padding: 12px;
            border: 1px solid #ddd;
        }
        th {
            background-color: #f2f2f2;
        }
    </style>
</head>
<body>
    <h1>Organism Directed Therapy</h1>
    <table>
        <thead>
            <tr>
                <th>Organism</th>
                <th>First-Choice</th>
                <th>Alternative Choice</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td rowspan="3">Streptococci</td>
                <td>Penicillin G or CefTRIAXone</td>
                <td>Vancomycin or First-generation cephalosporin or CefTRIAXone</td>
            </tr>
            <tr>
                <td>Penicillin G or Ampicillin + Gentamicin (for first 2 weeks, or entire course for enterococci)</td>
                <td>Vancomycin + Gentamicin for enterococci or Ampicillin + CefTRIAXone (for AMG-resistant enterococci or AMG-intolerant patient) or CefTRIAXone + Gentamicin (not for enterococcal endocarditis)</td>
            </tr>
            <tr>
                <td>Consult an infectious disease specialist.</td>
                <td>---</td>
            </tr>
            <tr>
                <td rowspan="4">Staphylococci (S aureus or coagulase-negative staphylococci) †</td>
                <td>Penicillin G</td>
                <td>Oxacillin or Nafcillin or First-generation cephalosporin or Vancomycin</td>
            </tr>
            <tr>
                <td>Oxacillin or Nafcillin with or without Gentamicin</td>
                <td>Vancomycin (for those highly allergic to beta-lactam antibiotics) or First-generation cephalosporin</td>
            </tr>
            <tr>
                <td>Vancomycin</td>
                <td>Daptomycin for right-sided endocarditis, maybe for left-sided</td>
            </tr>
            <tr>
                <td>Daptomycin</td>
                <td>Unknown</td>
            </tr>
            <tr>
                <td>Gram-negative enteric bacilli</td>
                <td>CefTAZidime or Cefepime or Cefotaxime or CefTRIAXone Plus gentamicin (or tobramycin or amikacin, depending on susceptibility)</td>
                <td>Broad-spectrum penicillin Plus gentamicin (or tobramycin or amikacin)</td>
            </tr>
            <tr>
                <td>HACEK group</td>
                <td>CefTRIAXone or Cefotaxime or Ampicillin-sulbactam</td>
                <td>Ampicillin (when susceptible) Plus aminoglycoside</td>
            </tr>
        </tbody>
    </table>
    <p><strong>KEY:</strong> AMG = aminoglycosides; HACEK = Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; MBC = minimum bactericidal concentration, MRSA = methicillin-resistant Staphylococcus aureus (includes resistance to oxacillin, nafcillin, and cephalosporins).</p>

    
        <div class="section-title">Contraindications/Precautions</div>  
        <p><strong>Acute respiratory failure</strong> may result when reconstituted colistimethate solution for inhalation is
        not used promptly. After reconstitution, colistimethate is hydrolyzed to form active components,
        including polymyxin E1, which has shown to cause localized inflammation of the airway epithelia
        and eosinophilic infiltration when administered by inhalation</p>

        <p><strong>Bronchospasms</strong> may occur with inhalation of colistin; consider premedication with a
        bronchodilator.</p>

        <p><strong>Clostridium difficile-associated diarrhea (CDAD),</strong> including mild diarrhea to fatal colitis, has
        been reported and may occur more than 2 months after administration. If CDAD is suspected or
        confirmed, discontinue any ongoing antibiotic therapy</p>

        <p>Concomitant use of sodium <strong>cephalothin</strong> should be avoided</p>

        <p>Increased risk of <strong>neuromuscular blockade</strong> leading to apnea in patients with renal impairment.
        Dosage adjustment should be reduced in proportion to the extent of the impairment</p>

        <p><strong>Respiratory arrest</strong> has been reported after IM administration</p>
        <p>Reversible and dose-dependent <strong>nephrotoxicity</strong> may occur</p>
        <p>Transient <strong>neurological disturbances</strong> (eg, circumoral paresthesia or numbness, tingling or
        formication of the extremities, generalized pruritus, vertigo, dizziness, and slurring of speech), may
        occur and dosage adjustments may be necessary</p>

    <!-- เส้นแบ่ง -->
    <hr>

        <div class="section-title">Adverse Effects</div> 
<p>The most commonly reported adverse effects are gastrointestinal upset, slurred speech, dizziness,
tingling of the extremities or tongue, itching, urticaria, rash, fever, respiratory distress, apnea, and
nephrotoxicity.<br>
Serum creatinine increased more than 0.5 mg/dL above baseline in 2 out of 18 neonates
administered IV colistin.<br>
Neither clinical nor laboratory adverse events were reported with aerosolized colistin in 8
neonates. Serum creatinine and blood urea nitrogen remained within normal limits 72 hours after
completion of colistin therapy.</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Monitoring</div>
          <p>Closely monitor for toxicity in pediatric patients. Monitor urine output, BUN, and serum
          creatinine.</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Pharmacology</div>
          <div class="section-title">Microbiology</div>
          <p>Colistimethate sodium is a surface active agent that is used to penetrate and disrupt the cell
          membrane of bacteria. It has demonstrated bactericidal activity against most strains of aerobic
          gram-negative microorganisms (Enterobacter aerogenes, Escherichia coli, Klebsiella pneumonia, and
          Pseudomonas aeruginosa) both in vitro and in clinical infections.</p>

          <div class="section-title">Pharmacokinetics</div>       
          <p>Higher serum levels were obtained at 10 minutes following IV administration compared with IM
          administration <br>
          Half-life was 2 to 3 hours after administration (either IM or IV) in both the adult and pediatric
          populations, including premature infants. The half-life was 2.6 hours in neonates (0 to 7 days) and
          2.3 hours in infants 7 days or older.<br>
          Urine levels ranged, on average, from 270 mcg/mL at 2 hours to 15 mcg/mL at 8 hours following IV
          administration and 200 mcg/mL to 25 mcg/mL over a similar time period with IM administration.</p>

          <p><strong>IV Administration</strong> Within 6 hours of IV colistin base 5 mg/kg, the colistin concentration was less
          than 2 mcg/mL in all 7 neonates (median 38 weeks gestation and 13 days postnatal age) after a single
          IV colistin base dose of 5 mg/kg/day.</p>
          <p><strong>Nebulization Administration:</strong> After a single-dose of ultrasonic-nebulized colistin base 4 mg/kg in
          6 neonates (median gestational age 39 weeks (32 to 39) and postnatal age 7 days (3 to 7)) with
          ventilator-associated pneumonia, 50% of tracheal aspirate concentrations of colistin were below 2
          mcg/mL 24 hours after administration. The ratio of colistin plasma concentrations-to-tracheal
          aspirate was 0.038 (3.8%)</p>
          <p>The following were the pharmacokinetic parameters for colistin in the tracheal aspirate and plasma
via nebulization and in the plasma via IV administration:</p>


<table>
        <thead>
            <tr>
                <th colspan="4">Single-Dose, Colistin Pharmacokinetics in Neonates</th>
            </tr>
            <tr>
                <th>Parameters</th>
                <th>Nebulization 4 mg/kg (n=6)*</th>
                <th>IV 5 mg/kg (mean (range)) (n=7)**</th>
                <th>Tracheal Aspirate Plasma Plasma</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td><strong>Cmax</strong></td>
                <td>24 mcg/mL (15.6 to 34.6 mcg/mL)</td>
                <td>0.59 mcg/mL (0.32 to 1.1 mcg/mL)</td>
                <td>3 mcg/mL</td>
            </tr>
            <tr>
                <td><strong>Tmax</strong></td>
                <td>1.8 hours (0.5 to 6 hours)</td>
                <td>1.9 hours</td>
                <td>1.3 hours</td>
            </tr>
            <tr>
                <td><strong>AUC (0 to 24)</strong></td>
                <td>147.6 mcg x hr/mL</td>
                <td>2.34 mcg x hr/mL</td>
                <td>21.1 mcg x hr/mL</td>
            </tr>
            <tr>
                <td><strong>AUC (0 to infinity)</strong></td>
                <td>183.8 mcg x hr/mL</td>
                <td>7.57 mcg x hr/mL</td>
                <td>25.3 mcg x hr/mL</td>
            </tr>
            <tr>
                <td><strong>Clearance of formed colistin</strong></td>
                <td>0.027 L/hr/kg</td>
                <td>1.01 L/hr/kg</td>
                <td>0.6 L/hr/kg</td>
            </tr>
            <tr>
                <td><strong>Half-life</strong></td>
                <td>9.8 hours</td>
                <td>10.2 hours</td>
                <td>9 +/- 6.5 hours</td>
            </tr>
            <tr>
                <td><strong>Vd of formed colistin</strong></td>
                <td>0.46 L/kg</td>
                <td>11.7 L/kg</td>
                <td>7.7 +/- 9.3 L/kg</td>
            </tr>
        <tr>
            <td colspan="4" style="text-align: left;"><strong>KEY:</strong> Cmax = maximum colistin concentration, Tmax = time to maximum colistin concentration, AUC = area under the concentration time curve, Vd = apparent volume of distribution</td>
        </tr>
            </tbody>
    </table>

          <div class="section-title">Pharmacodynamics</div>  
          <p>The ratio of AUC/MIC of colistin base is the most predictive of antibacterial activity.</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Special Considerations/Preparation</div>
          <p>Each vial containing colistimethate sodium (pentasodium colistin-methanesulfonate) is equivalent to
          150 mg of colistin base activity. Colistin base 1 mg is equivalent to 2.4 mg of colistimethate
          sodium. Colistimethate sodium is 12,500 international units/mg and colistin base is 30,000
          international units/mg.<br>
          Store vials at controlled room temperature between 20 and 25 degrees C (68 and 77 degrees F),
          with excursions permitted between 15 and 30 degrees C (59 and 86 degrees F).</p>

          <div class="section-title">Intravenous:</div>
          <p>Reconstitute 150 mg (colistin base) vial with 2 mL sterile water for injection for a resulting
          concentration of 75 mg/mL colistin base; swirl gently to avoid frothing.
          Once diluted with sterile water for injection, store solution up to 7 days, between 20 and 25
          degrees C (68 and 77 degrees F) or refrigerated between 2 and 8 degrees C (36 and 46 degrees
          F).<br>
          Colistimethate for continuous infusion should be mixed with NS, D5NS, D5W, D5-0.45%NaCl, D5-
          0.225%NaCl, LR, or 10% invert sugar solution and used within 24 hours.</p>

          <p><strong>Inhalation:</strong> Use <strong>immediately</strong> after mixed. Do not use after 24 hours. In solution, colistimethate undergoes spontaneous hydrolysis to form its 2 active components polymyxin E1 (colistin A), which
          is toxic to the lungs, and polymyxin E2 (colistin B). Use after 24 hours can result in increased
          colistin concentration and the potential for increased lung toxicity.</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Solution Compatibility</div>
          <p>NS, D5NS, D5 0.45%NS, D5W</p>

    <!-- เส้นแบ่ง -->
    <hr>

          <div class="section-title">Terminal Injection Site Compatibility</div>
          <p>Aminophylline, atropine sulfate, calcium chloride, calcium gluconate, chloramphenicol sodium
          succinate, chlorothiazide sodium, chlorpheniramine maleate, chlorpromazine hydrochloride,
          clarithromycin, cloxacillin sodium, cyclophosphamide, dexamethasone sodium phosphate, digoxin,
          edetate calcium disodium, epinephrine hydrochloride, ergonovine maleate, erythromycin
          lactobionate, furosemide, gallamine triethiodide, gentamicin sulfate, heparin sodium, hydralazine
          hydrochloride, hydrocortisone sodium succinate, isoproterenol hydrochloride, kanamycin sulfate,
          lidocaine hydrochloride, lincomycin hydrochloride, mechlorethamine hydrochloride,
          mephentermine sulfate, metaraminol bitartrate, methohexital sodium, methyldopate hydrochloride,
          nalorphine hydrobromide, norepinephrine bitartrate, oxytocin, penicillin G potassium, penicillin G
          sodium, phenobarbital sodium, phentolamine mesylate, polymyxin B sulfate, potassium chloride,
          procainamide hydrochloride, prochlorperazine mesylate, promazine hydrochloride, promethazine
          hydrochloride, propranolol hydrochloride, streptomycin sulfate, succinylcholine chloride,
          trimetaphan camsylate, tubocurarine chloride.</p>

        <div class="button-group">
            <a href="javascript:history.back()" class="back-button-secondary">Back</a>
            <a href="{{ url_for('index') }}" class="back-button">Back to Home</a>
        </div>
    
        <footer>
            <p>Developed by Sukhontha Boonsookchan | update {{ update_date }}</p>
        </footer>

</body>
</html>
